{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.2","upperLimit":"21.9","value":"15.0"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"17.3","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Defined as time from randomization to the first documentation of event where events considered are 1) disease progression, per RECIST, prior to surgery, 2) surgery with R2 resection, 3) recurrent disease following surgery, or 4) death due to any cause. Will be estimated using the method of Kaplan-Meier in each arm and compared between treatment groups using the log-rank test. The correlation between pathologic complete response (pCR) status and event-free survival time will be assessed by Cox model with landmark approach.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 8 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.","id":"OG000","title":"Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)"},{"description":"Patients receive 7 cycles of mFOLFIRINOX. One cycle is 14 days. mFOLFIRINOX consists of oxaliplatin, irinotecan, leucovorin and 5-FU. Patients receive radiation therapy then undergo surgery and receive 4 cycles of FOLFOX 4-12 weeks after surgery. FOLFOX consists of oxaliplatin, leucovorin and 5-FU.","id":"OG001","title":"Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)"}],"paramType":"MEDIAN","populationDescription":"Excluded from analysis were 6 patients that withdrew or progressed prior to treatment.","reportingStatus":"POSTED","timeFrame":"4 years and 7 months","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}